The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 462.50
Bid: 455.00
Ask: 470.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.297%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 462.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Journal of Infection Prevention: TSTL wipes study

24 Jan 2017 07:00

RNS Number : 8777U
Tristel PLC
24 January 2017
 

 

Tristel plc

("Tristel" or "the Company")

 

Tristel's chlorine dioxide wipes are proposed as an alternative to traditional high-level disinfection soaking procedures published in Journal of Infection Prevention

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that a study conducted at the Centre Hospitalier Régional Universitaire de Lille, France, compared its Trio Wipes System with a detergent and a peracetic acid disinfectant manufactured by Laboratoires Anios, Hellemmes, France. Anios is France's leading infection prevention company and has recently been acquired by Ecolab Inc. of the United States.

 

The study found that the wiping procedure with Tristel's chlorine dioxide chemistry displayed more than a 5-log reduction of four strains of bacteria in 30 seconds and a 4-log reduction of bacterial spores in 2 minutes. The soaking procedure with peracetic acid displayed similar results as chlorine dioxide against bacteria but took 10 minutes to do so, and was unable to achieve a 4-log reduction in bacterial spores.

 

Bacterial spores are considered to be the most resistant organisms to disinfectants and the ability to kill them both in high numbers and quickly is the distinguishing feature of the highest performing products. Peracetic acid is the most widely used high-level disinfectant throughout Europe and soaking an instrument, rather than wiping it, is considered to be the traditional method to disinfect a medical device. The medical device used in the study was a flexible nasendoscope used in Ear, Nose and Throat (ENT) departments. ENT is one of Tristel's main niche markets within hospitals.

 

The study has been published in the Journal of Infection Prevention (Noureddine Henoun Loukili, Nadine Lemaitre, Benoit Guery, Olivier Gaillot, Dominique Chevalier and Geoffrey Mortuaire (2017) and is titled 'Is a chlorine dioxide wiping procedure suitable for the high-level disinfection of nasendoscopes', Journal of Infection Prevention, pp. 1-6 DOI: 10.1177/1757177416679879). Preliminary results of the study were reported by an RNS Reach on 1 December 2015.

 

The Tristel Wipes System is a unique, patented decontamination method for non-lumened scopes and probes. It has been a very significant sales success for the Company globally. Worldwide sales of the Wipes System in the financial year ending June 2016 were £8.7m.

 

Paul Swinney, CEO, comments: "We are pleased to see the publication in a peer-reviewed journal of this significant study comparing our Wipes System with peracetic acid, which is the most widely used high-level disinfectant chemistry in Europe and probably the United States also. The results affirm the key advantages of our Wipes over alternative chemistries and disinfection methods. These advantages are the level and speed of kill of the most resistant organisms. This is the twenty-sixth peer-reviewed and published scientific paper featuring Tristel products - a body of evidence of our products' attributes that forms one of our Company's key strengths.

 

"France is one of our key target markets for growth and this study can only help with this ambition. We sell our products through a distributor in France."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

finnCap

Tel: 020 7600 1658

Geoff Nash/ Giles Rolls (Corporate Finance)

Alice Lane (Corporate Broking)

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABJMITMBITBTR
Date   Source Headline
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.